PGGT1B

Across TCGA pan-cancer cohorts, PGGT1B RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PGGT1B’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where PGGT1B RNA is repressed in tumor relative to normal tissue. In most cancer types PGGT1B is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

THCA, COAD, and LUSC are the cancer types where PGGT1B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PGGT1B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−1.017	<.001	11	view →
COAD	Female	All	−0.829	<.001	7	view →
LUSC	All	II,III,IV	−0.515	<.001	7	view →
KICH	All	All	−0.735	<.001	6	view →
BRCA	All	II,III,IV	+0.232	.004	6	view →
LIHC	All	All	+0.357	<.001	5	view →
CHOL	Male	All	+1.063	<.001	4	view →
KIRC	All	All	+0.206	.006	4	view →
READ	Female	All	−0.756	<.001	3	view →
UCEC	All	All	−0.514	.001	2	view →
LUAD	Female	II,III,IV	−0.380	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PGGT1B–THCA

Open the THCA breakdown →